ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

S J H Vijverberg; E S Koster; R Tavendale; M Leusink; L Koenderman; J A M Raaijmakers; D S Postma; G H Koppelman; S W Turner; S Mukhopadhyay; S M Tse; K G Tantisira; D B Hawcutt; B Francis; M Pirmohamed; M Pino-Yanes; C Eng; E G Burchard; C N A Palmer; A H Maitland-van der Zee

doi:10.1111/cea.12492

ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

S J H Vijverberg, E S Koster, R Tavendale, M Leusink, L Koenderman, J A M Raaijmakers, D S Postma, G H Koppelman, S W Turner, S Mukhopadhyay, S M Tse, K G Tantisira, D B Hawcutt, B Francis, M Pirmohamed, M Pino-Yanes, C Eng, E G Burchard, C N A Palmer, A H Maitland-van der Zee (Corresponding Author)

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

20 Downloads (Pure)

Abstract

BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.

METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed.

RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively.

CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.

Original language	English
Pages (from-to)	1051-1059
Number of pages	9
Journal	Clinical & experimental allergy
Volume	45
Issue number	6
Early online date	16 May 2015
DOIs	https://doi.org/10.1111/cea.12492
Publication status	Published - Jun 2015

Bibliographical note

Keywords

childhood asthma
corticosteroids
exacerbations
pharmacogenomics
ST13

Access to Document

10.1111/cea.12492Licence: Unspecified

ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults
This is the peer reviewed version of the following article: Vijverberg, SJH, Koster, ES, Tavendale, R, Leusink, M, Koenderman, L, Raaijmakers, JAM, Postma, DS, Koppelman, GH, Turner, SW, Mukhopadhyay, S, Tse, SM, Tantisira, KG, Hawcutt, DB, Francis, B, Pirmohamed, M, Pino-Yanes, M, Eng, C, Burchard, EG, Palmer, CNA & Maitland-van der Zee, AH 2015, 'ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults' Clinical & experimental allergy, vol 45, no. 6, pp. 1051-1059, which has been published in final form at 10.1111/cea.12492. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Accepted author manuscript, 1.4 MBLicence: Unspecified

Cite this

Vijverberg, S. J. H., Koster, E. S., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J. A. M., Postma, D. S., Koppelman, G. H., Turner, S. W., Mukhopadhyay, S., Tse, S. M., Tantisira, K. G., Hawcutt, D. B., Francis, B., Pirmohamed, M., Pino-Yanes, M., Eng, C., Burchard, E. G., Palmer, C. N. A., & Maitland-van der Zee, A. H. (2015). ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clinical & experimental allergy, 45(6), 1051-1059. https://doi.org/10.1111/cea.12492

Vijverberg, SJH, Koster, ES, Tavendale, R, Leusink, M, Koenderman, L, Raaijmakers, JAM, Postma, DS, Koppelman, GH, Turner, SW, Mukhopadhyay, S, Tse, SM, Tantisira, KG, Hawcutt, DB, Francis, B, Pirmohamed, M, Pino-Yanes, M, Eng, C, Burchard, EG, Palmer, CNA & Maitland-van der Zee, AH 2015, 'ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults', Clinical & experimental allergy, vol. 45, no. 6, pp. 1051-1059. https://doi.org/10.1111/cea.12492

@article{aa000f8cf9984bb9b4a8c3d11c274b16,

title = "ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults",

abstract = "BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.",

keywords = "childhood asthma, corticosteroids, exacerbations, pharmacogenomics, ST13",

author = "Vijverberg, {S J H} and Koster, {E S} and R Tavendale and M Leusink and L Koenderman and Raaijmakers, {J A M} and Postma, {D S} and Koppelman, {G H} and Turner, {S W} and S Mukhopadhyay and Tse, {S M} and Tantisira, {K G} and Hawcutt, {D B} and B Francis and M Pirmohamed and M Pino-Yanes and C Eng and Burchard, {E G} and Palmer, {C N A} and {Maitland-van der Zee}, {A H}",

note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = jun,

doi = "10.1111/cea.12492",

language = "English",

volume = "45",

pages = "1051--1059",

journal = "Clinical & experimental allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

AU - Vijverberg, S J H

AU - Koster, E S

AU - Tavendale, R

AU - Leusink, M

AU - Koenderman, L

AU - Raaijmakers, J A M

AU - Postma, D S

AU - Koppelman, G H

AU - Turner, S W

AU - Mukhopadhyay, S

AU - Tse, S M

AU - Tantisira, K G

AU - Hawcutt, D B

AU - Francis, B

AU - Pirmohamed, M

AU - Pino-Yanes, M

AU - Eng, C

AU - Burchard, E G

AU - Palmer, C N A

AU - Maitland-van der Zee, A H

PY - 2015/6

Y1 - 2015/6

N2 - BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.

AB - BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS.METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed.RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively.CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.

KW - childhood asthma

KW - corticosteroids

KW - exacerbations

KW - pharmacogenomics

KW - ST13

U2 - 10.1111/cea.12492

DO - 10.1111/cea.12492

M3 - Article

C2 - 25616159

SN - 0954-7894

VL - 45

SP - 1051

EP - 1059

JO - Clinical & experimental allergy

JF - Clinical & experimental allergy

IS - 6

ER -

ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this